Persistence and adherence to disease modifying drugs among patients with multiple sclerosis

Current Medical Research and Opinion

Volumn 26, Issue 3, 2010, Pages 663-674

  Reynolds, Matthew W ^a   Stephen, Reejis ^a   Seaman, Chris ^a   Rajagopalan, Kitty ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b BIOGEN   (United States)

Author keywords

Adherence; Avonex; Beta; Betaseron; Compliance; Copaxone; Immunomodulatory agents; Interferon; Persistence; Rebif

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; COMORBIDITY; DATA BASE; DISEASE EXACERBATION; DRUG COST; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SEX RATIO; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MODELS, THEORETICAL; MULTIPLE SCLEROSIS; PEPTIDES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 76949100155     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903554257     Document Type: Article

References (23)

1. Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40:1280-1288
2. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-74; discussion 75-77
3. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J manage Care 2005;11:449-457
4. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50: 105-116
5. Johnson ES, Mozaffari E. Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies. Am J Manage Care 2002;8:S249-54
6. Goodin DS, Frohman EM, Garmany Jr GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178
7. Rich SR, Coleman IC, Cook R, et al. Stepped-care approach to treating MS: a managed care treatment algorithm. J Manag Care Pharm 2004;10:S26-32
8. Clerico M, Barbero P, Contessa G, et al. Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci 2007;259:104-108
9. Tremlett H, Van der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf 2008;17:565-576
10. Milanese C, La Mantia L, Palumbo R, et al. A post-marketing study on inter-feron beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003;74:1689-1692
11. Ruggieri RM, Settipani N, Viviano L, et al. Long-term interferon-beta treatment for multiple sclerosis. Neurol Sci 2003;24:361-364
12. Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments-a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 2005; 12:425-431
13. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50
14. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003;61:551-554
15. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306-309
16. Hauser S, Goodin D. Multiple sclerosis and other demyelinating diseases. In: Kasper DL, Braunwald E, Jameson JL, et al., eds. Harrison's Principles of Internal Medicine, 16th edn. New York: McGraw-Hill, 2003
17. Caon C, Din M, Ching W, et al. Clinical course after change of immunomo-dulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2006; 13:471-474
18. Hudson M, Rahme E, Richard H, et al. Comparison of measures of medication persistency using a prescription drug database. Am Heart J 2007;153:59-65
19. Clark DO, Von Korff M, Saunders K, et al. A chronic disease score with empirically derived weights. Med Care 1995;33:783-795
20. Frohman EM. Multiple sclerosis. Med Clin North Am 2003;87:867-97, viii-ix
21. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-461
22. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: John Wiley & Sons, 1999
23. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42:200-209